Format

Send to

Choose Destination
See comment in PubMed Commons below
Endocrinol Diabetes Metab Case Rep. 2014;2014:140048. doi: 10.1530/EDM-14-0048. Epub 2014 Aug 1.

A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma.

Author information

1
Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA.
2
Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège , Liège , Belgium.
3
Department of Neurosurgery, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA.
4
Department of Pathology, Centre Hospitalier Universitaire de Liège, University of Liège , Liège , Belgium.

Abstract

Heterozygous germline inactivating mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene lead to pituitary adenomas that most frequently present in the setting of familial isolated pituitary adenoma syndrome, usually as somatotropinomas and prolactinomas. More recently, they have been found in a significant percentage of young patients presenting with pituitary macroadenoma without any apparent family history. We describe the case of a 19-year-old man who presented with a gigantic somatotropinoma. His family history was negative. His peripheral DNA showed a heterozygous AIP mutation (p.I13N), while tumor tissue only had the mutated allele, showing loss of heterozygosity (LOH) and suggesting that the mutation caused the disease.

LEARNING POINTS:

AIP mutations may be observed in sporadic somatotrope adenomas occurring in young patients.LOH is a strong indicator that an AIP variant is disease causing.Somatotrope adenomas in carriers of AIP mutations are generally larger and more difficult to cure.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center